Cicatrix Cream in cutaneous striae
Phase 2
- Conditions
- Cutaneous striae
- Registration Number
- RPCEC00000090
- Lead Sponsor
- Catalysis S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patient with cutaneous striae Patients aged 10 years and 18 years of both sexes (ID card) Signed the Informed consent
Exclusion Criteria
Patient that refer manifestations of high sensibility to the medication or to some of the. components of the product Patient that don’t want to participate in the study Patient not very cooperative Responsible family not very cooperative
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the striaes (Excellent (E) Disappearance the striaes to the 4 months of initiate the treatment, Good (B): Disappearance of the striaes more than 50 %, Regular (R): Disappearance of the striaes less than 50 %, Bad (M): That stays the clinical square without variation). Measurement time: monthly for 4 months.
- Secondary Outcome Measures
Name Time Method Extension and reduction of the striaes expressed in centimetres (Good: Reduction of more than 50% in centimeters, Regular: Reduction of less than 50% in centimetres, Bad: No reduction). Measurement time: monthly for 4 months Security depends of the Adverse Events (AE)(Good: without AE, Regular: There are AE but it is possible to continue the treatment, Bad: Interruption of the treatment due AE). Measurement time: monthly for 4 months.